RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".

Oronsky, Bryan; Carter, Corey A; Caroen, Scott; Scribner, Curtis; Oronsky, Arnold; Reid, Tony R

Oronsky, Bryan; Carter, Corey A; Caroen, Scott; Scribner, Curtis; Oronsky, Arnold; Reid, Tony R.

Afiliação

Oronsky B; Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
Carter CA; Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
Caroen S; Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
Scribner C; Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
Oronsky A; Clinical and Scientific Department, InterWest Partners, Menlo Park, CA, USA.
Reid TR; Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.

Oncoimmunology ; 9(1): 1746172, 2020 04 03.

Article em En | MEDLINE | ID: mdl-33457091

Assuntos

Azetidinas; Antígeno CD47; Nitrocompostos

Palavras-chave

CD47; Immunotherapy; MYC; erythrophagoimmunotherapeutic; hemoglobin; small molecule; tumor associated macrophage

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Antígeno CD47 Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google